Product Name |
5-HT2 Receptor |
5-HT1 Receptor |
5-HT3 Receptor |
5-HT5 Receptor |
5-HT6 Receptor |
5-HT7 Receptor |
5-HT4 Receptor |
5-HT2 Receptor Selectivity |
Purity |
Chlorpromazine hydrochloride |
5-HT2A Receptor, Ki: 8.9 nM
|
|
|
|
|
|
|
Selective Antagonist
|
99.90% |
Harmine |
5-HT2A Receptor, Ki: 397 nM
|
|
|
|
|
|
|
Selective Inhibitor
|
99.93% |
SCH-23390 hydrochloride |
5-HT2C Receptor, Ki: 9.3 nM
|
|
|
|
|
|
|
Selective Agonist
|
99.31% |
SKF-83566 |
5-HT2 Receptor, Ki: 11 nM
|
|
|
|
|
|
|
Selective Antagonist
|
99.86% |
Risperidone |
5-HT2A Receptor, Ki: 4.8 nM
|
|
|
|
|
|
|
Selective Inhibitor
|
98.01% |
Puerarin |
|
|
|
|
|
|
|
Selective Antagonist
|
99.20% |
Ketanserin |
|
|
|
|
|
|
|
Selective Antagonist
|
98.57% |
Pimavanserin |
5-HT2A Receptor, pIC50: 8.7
|
|
|
|
|
|
|
Selective Inhibitor
|
99.99% |
Perphenazine |
5-HT2A Receptor, Ki: 5.6 nM
|
|
|
|
|
|
|
Selective Inhibitor
|
99.72% |
Asenapine maleate |
5-HT2A Receptor, Ki: 0.06 nM
5-HT2C Receptor, Ki: 0.03 nM
|
|
|
|
|
5-HT7 Receptor, Ki: 0.13 nM
|
|
Selective Antagonist
|
99.95% |
Volinanserin |
5-HT2 Receptor, Ki: 0.36 nM
|
|
|
|
|
|
|
Selective Antagonist
|
99.71% |
Agomelatine |
5-HT2C Receptor, pKi: 6.4 (native porcine)
5-HT2C Receptor, pKi: 6.2 (human)
|
|
|
|
|
|
|
Selective Antagonist
|
98.77% |
Cyproheptadine hydrochloride |
|
|
|
|
|
|
|
Selective Antagonist
|
99.98% |
Nefazodone hydrochloride |
5-HT2A Receptor, Ki: 5.8 nM
|
|
|
|
|
|
|
Selective Antagonist
|
99.71% |
Pimavanserin tartrate |
5-HT2A Receptor, pIC50: 8.73
5-HT2A Receptor, pKi: 9.3
|
|
|
|
|
|
|
Selective Inhibitor
|
99.50% |
Pizotifen |
|
|
|
|
|
|
|
Selective Antagonist
|
99.73% |
SB 242084 |
5-HT2C Receptor, pKi: 9.0
|
|
|
|
|
|
|
Selective Antagonist
|
99.47% |
Ketanserin tartrate |
|
|
|
|
|
|
|
Selective Antagonist
|
99.97% |
Ritanserin |
5-HT2 Receptor, IC50: 0.9 nM
|
|
|
|
|
|
|
Selective Antagonist
|
>99.0% |
Trimipramine maleate |
5-HT2 Receptor, pKi: 8.10
|
|
|
|
|
|
|
Selective Antagonist
|
99.84% |
Cinanserin hydrochloride |
5-HT2 Receptor, Ki: 41 nM
|
|
|
|
|
|
|
Selective Antagonist
|
99.74% |
Vabicaserin hydrochloride |
5-HT2C Receptor, EC50: 8 nM
|
|
|
|
|
|
|
Selective Agonist
|
98.99% |
Sarpogrelate hydrochloride |
5-HT2A Receptor, pKi: 8.52
5-HT2B Receptor, pKi: 6.57
5-HT2C Receptor, pKi: 7.43
|
|
|
|
|
|
|
Selective Antagonist
|
>98.0% |
Blonanserin |
5-HT2A Receptor, Ki: 0.812 nM
5-HT2C Receptor, Ki: 26.4 nM
|
|
|
|
5-HT6 Receptor, Ki: 11.7 nM
|
|
|
Selective Antagonist
|
99.77% |
Asenapine hydrochloride |
5-HT2A Receptor, Ki: 0.06 nM
5-HT2C Receptor, Ki: 0.03 nM
|
|
|
|
|
5-HT7 Receptor, Ki: 0.13 nM
|
|
Selective Antagonist
|
99.39% |
Lidanserin |
|
|
|
|
|
|
|
Selective Antagonist
|
>98.0% |
Nelotanserin |
5-HT2A Receptor, IC50: 1.7 nM
5-HT2C Receptor, IC50: 79 nM
5-HT2B Receptor, IC50: 791 nM
|
|
|
|
|
|
|
Selective Antagonist
|
99.79% |
Pimethixene maleate |
5-HT2A Receptor, pKi: 10.22
5-HT2B Receptor, pKi: 10.44
5-HT2C Receptor, pKi: 8.42
|
5-HT1A Receptor, pKi: 7.63
|
|
|
|
|
|
Selective Antagonist
|
>98.0% |
PRX-08066 |
5-HT2B Receptor, IC50: 3.4 nM
|
|
|
|
|
|
|
Selective Antagonist
|
97.04% |
Roluperidone |
5-HT2A Receptor, Ki: 7.53 nM
|
|
|
|
|
|
|
Selective
|
98.08% |
Agomelatine hydrochloride |
5-HT2C Receptor, pKi: 6.4 (native porcine)
5-HT2C Receptor, pKi: 6.2 (human)
|
|
|
|
|
|
|
Selective Antagonist
|
99.49% |
Cyproheptadine hydrochloride sesquihydrate |
|
|
|
|
|
|
|
Selective Antagonist
|
99.20% |
Naftidrofuryl oxalate |
|
|
|
|
|
|
|
Selective Antagonist
|
95.81% |
Isocorynoxeine |
5-HT2A Receptor, IC50: 72.4 μM
|
|
|
|
|
|
|
Selective Inhibitor
|
99.97% |
SKF-83566 hydrobromide |
5-HT2 Receptor, Ki: 11 nM
|
|
|
|
|
|
|
Selective Antagonist
|
|
Fananserin |
5-HT2 Receptor, Ki: 0.37 nM
|
|
|
|
|
|
|
Selective Antagonist
|
99.71% |
Spiramide |
|
5-HT1A Receptor, Ki: 50 nM
5-HT1C Receptor, Ki: 4300 nM
|
|
|
|
|
|
Selective Antagonist
|
98.81% |
Risperidone hydrochloride |
5-HT2 Receptor, Ki: 4.8 nM
|
|
|
|
|
|
|
Selective Antagonist
|
|
Pimethixene |
5-HT2A Receptor, pKi: 10.22
5-HT2B Receptor, pKi: 10.44
5-HT2C Receptor, pKi: 8.42
|
5-HT1A Receptor, pKi: 7.63
|
|
|
|
|
|
Selective Antagonist
|
|
Blonanserin D5 |
|
|
|
|
|
|
|
Selective Antagonist
|
|
cis-Urocanic acid |
|
|
|
|
|
|
|
Selective Agonist
|
99.92% |
SB-215505 |
5-HT2B Receptor, pKi: 8.3
5-HT2A Receptor, pKi: 6.77
5-HT2C Receptor, pKi: 7.66
|
|
|
|
|
|
|
Selective Antagonist
|
|
SB 243213 |
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
Selective Antagonist
|
98.62% |
3-Hydroxy agomelatine |
5-HT2C Receptor, IC50: 3.2 μM
5-HT2C Receptor, Ki: 1.8 μM
|
|
|
|
|
|
|
Selective Antagonist
|
|
Blonanserin D8 |
|
|
|
|
|
|
|
Selective Antagonist
|
|
SCH-23390 maleate |
5-HT2C Receptor, Ki: 9.3 nM
|
|
|
|
|
|
|
Selective Agonist
|
|
7-Desmethyl-3-hydroxyagomelatine |
|
|
|
|
|
|
|
Selective Antagonist
|
|
Flumexadol |
5-HT2C Receptor, Ki: 25 nM
|
|
|
|
|
|
|
Selective Agonist
|
98.50% |
Iferanserin |
|
|
|
|
|
|
|
Selective Antagonist
|
|
Eplivanserin (mixture) |
|
|
|
|
|
|
|
Selective Antagonist
|
99.95% |
Org-12962 |
5-HT2C Receptor, pEC50: 7.01
5-HT2A Receptor, pEC50: 6.38
5-HT2B Receptor, pEC50: 6.28
|
|
|
|
|
|
|
Selective Agonist
|
>98.0% |
(Rac)-WAY-161503 |
5-HT2C Receptor, Ki: 4 nM
5-HT2C Receptor, EC50: 12 nM
|
|
|
|
|
|
|
Selective Agonist
|
>99.0% |
Clocapramine hydrochloride hydrate |
|
|
|
|
|
|
|
Selective Antagonist
|
|
Opiranserin |
5-HT2A Receptor, IC50: 1.3 μM
|
|
|
|
|
|
|
Selective Antagonist
|
|
RS-127445 |
5-HT2B Receptor, pKi: 9.5 nM
|
|
|
|
|
|
|
Selective Antagonist
|
|
Org-12962 hydrochloride |
5-HT2C Receptor, pEC50: 7.01
5-HT2A Receptor, pEC50: 6.38
5-HT2B Receptor, pEC50: 6.28
|
|
|
|
|
|
|
Selective Agonist
|
|
(R)-Praziquantel D11 |
|
|
|
|
|
|
|
Selective Agonist
|
|
Harmine hydrochloride |
5-HT2A Receptor, Ki: 397 nM
|
|
|
|
|
|
|
Selective Inhibitor
|
|
Risperidone mesylate |
5-HT2A Receptor, Ki: 4.8 nM
|
|
|
|
|
|
|
Selective Inhibitor
|
|
Agomelatine (L(+)-Tartaric acid) |
5-HT2C Receptor, pKi: 6.4 (native porcine)
5-HT2C Receptor, pKi: 6.2 (human)
|
|
|
|
|
|
|
Selective Antagonist
|
99.82% |
Pizotifen malate |
|
|
|
|
|
|
|
Selective Antagonist
|
|
Clocapramine |
|
|
|
|
|
|
|
Selective Antagonist
|
|
(4E)-SUN9221 |
|
|
|
|
|
|
|
Selective Antagonist
|
|
5-HT2 antagonist 1 |
|
|
|
|
|
|
|
Selective Antagonist
|
|
5-HT2A antagonist 1 |
|
|
|
|
|
|
|
Selective Antagonist
|
|
Olanzapine |
5-HT2A Receptor, Ki: 4 nM
5-HT2C Receptor, Ki: 11 nM
|
|
5-HT3 Receptor, Ki: 57 nM
|
|
|
|
|
Pan Antagonist
|
99.89% |
Sertindole |
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
Pan Antagonist
|
99.76% |
Brexpiprazole |
5-HT2A Receptor, Ki: 0.47 nM
|
5-HT1A Receptor, Ki: 0.12 nM
|
|
|
|
|
|
Pan Modulator
|
99.40% |
Amitriptyline hydrochloride |
5-HT2A Receptor, IC50: 4 nM
5-HT2B Receptor, IC50: 40 nM
5-HT2C Receptor, IC50: 6 nM
|
5-HT1A Receptor, IC50: 450 nM
5-HT1B Receptor, IC50: 40 nM
|
|
|
|
|
|
Pan Inhibitor
|
99.56% |
Lumateperone tosylate |
5-HT2A Receptor, Ki: 0.54 nM
|
|
|
|
|
|
|
Pan Antagonist
|
99.21% |
Methiothepin mesylate |
5-HT2A Receptor, pKi: 8.50
5-HT2B Receptor, pKi: 8.68
5-HT2C Receptor, pKi: 8.35
|
5-HT1A Receptor, pKd: 7.10
5-HT1B Receptor, pKd: 7.28
5-HT1C Receptor, pKd: 7.56
5-HT1D Receptor, pKd: 6.99
|
|
5-HT5A Receptor, pKd: 7.0
5-HT5B Receptor, pKd: 7.8
|
5-HT6 Receptor, pKd: 8.74
|
5-HT7 Receptor, pKd: 8.99
|
|
Pan Antagonist
|
99.32% |
Ziprasidone |
|
Rat 5-HT1A Receptor, Ki: 3.4 nM
human 5-HT1A Receptor, Ki: 2.5 nM
|
|
|
|
|
|
Pan Antagonist
|
98.69% |
Quetiapine |
5-HT2A Receptor, pKi: 7.54
5-HT2C Receptor, pKi: 5.55
|
5-HT1A Receptor, pKi: 5.74
5-HT1A Receptor, pEC50: 4.77
|
|
|
|
|
|
Pan Agonist
|
99.96% |
Mirtazapine |
5-HT2 Receptor, pKi: 8.05
|
|
|
|
|
|
|
Pan Antagonist
|
99.97% |
Tegaserod maleate |
5-HT2B Receptor (Antagonist)
|
|
|
|
|
|
|
Pan Modulator
|
99.75% |
Flibanserin |
5-HT2A Receptor, Ki: 49 nM
|
5-HT1A Receptor, Ki: 1 nM
|
|
|
|
|
|
Pan Modulator
|
99.10% |
Quetiapine hemifumarate |
5-HT2A Receptor, pKi: 7.54
5-HT2C Receptor, pKi: 5.55
|
5-HT1A Receptor, pKi: 5.74
5-HT1A Receptor, pEC50: 4.77
|
|
|
|
|
|
Pan Agonist
|
98.24% |
GSK163090 |
5-HT2A Receptor, pKi: 6
5-HT2B Receptor, pKi: 6.3
5-HT2C Receptor, pKi: 5.8
|
5-HT1A Receptor, pKi: 9.4
5-HT1B Receptor, pKi: 8.5
5-HT1D Receptor, pKi: 9.7
|
|
|
Human 5-HT6 Receptor, pKi: <5.3
|
Human 5-HT7 Receptor , pKi: 6.8
|
|
Pan Antagonist
|
99.95% |
RS-127445 hydrochloride |
5-HT2A Receptor, pKi: 6.3
5-HT2C Receptor, pKi: 6.4
5-HT2B Receptor, pKi: 9.5
|
|
|
|
|
|
|
Pan Antagonist
|
99.68% |
Asenapine |
5-HT2A Receptor, pKi: 10.2
5-HT2C Receptor, pKi: 10.5
5-HT2B Receptor, pKi: 9.8
|
5-HT1A Receptor, pKi: 8.6
5-HT1B Receptor, pKi: 8.4
|
|
|
|
|
|
Pan Antagonist
|
98.81% |
BRL 54443 |
5-HT2A Receptor, Ki: 1259 nM
5-HT2B Receptor, Ki: 100 nM
5-HT2C Receptor, Ki: 316 nM
|
5-HT1E Receptor, Ki: 1.1 nM
5-HT1F Receptor, Ki: 0.7 nM
5-HT1A Receptor, Ki: 63 nM
5-HT1B Receptor, Ki: 126 nM
5-HT1D Receptor, Ki: 63 nM
|
|
|
5-HT6 Receptor, Ki: >10,000 nM
|
5-HT7 Receptor, Ki: >10,000 nM
|
|
Pan Agonist
|
99.39% |
Iloperidone |
Rat 5-HT2 Receptor, Ki: 3.1 nM
Human 5-HT2A Receptor, Ki: 5.6 nM
Human 5-HT2C Receptor, Ki: 42.8 nM
|
Rat 5-HT1A Receptor, Ki: 168 nM
|
|
|
Rat 5-HT6 Receptor, Ki: 42.7 μM
|
Rat 5-HT7 Receptor, Ki: 21.6 nM
|
|
Pan Antagonist
|
99.64% |
Nuciferine |
5-HT2C Receptor, IC50: 131 nM
5-HT2A Receptor, IC50: 478 nM
5-HT2B Receptor, IC50: 1 μM
|
5-HT1A Receptor, EC50: 3.2 μM
|
|
|
5-HT6 Receptor, EC50: 700 nM
|
5-HT7 Receptor, IC50: 150 nM
|
|
Pan Modulator
|
99.66% |
SEP-363856 hydrochloride |
5-HT2A Receptor, EC50: >10 μM
5-HT2C Receptor, EC50: 30 μM
|
5-HT1A Receptor, EC50: 2.3 μM
5-HT1B Receptor, EC50: 15.6 μM
5-HT1D Receptor, EC50: 0.262 μM
|
|
|
|
5-HT7 Receptor, EC50: 6.7 μM
|
|
Pan Agonist
|
99.78% |
Temanogrel |
5-HT2A Receptor, Ki: 4.9 nM
|
|
|
|
|
|
|
Pan Antagonist
|
98.94% |
SB-200646A |
5-HT2B Receptor, pKi: 7.5
5-HT2C Receptor, pKi: 6.9
5-HT2A Receptor, pKi: 5.2
|
|
|
|
|
|
|
Pan Antagonist
|
99.47% |
Arotinolol |
|
|
|
|
|
|
|
Pan Antagonist
|
98.18% |
Eltoprazine hydrochloride |
|
5-HT1A Receptor
5-HT1B Receptor
|
|
|
|
|
|
Pan Modulator
|
99.85% |
Perospirone |
5-HT2A Receptor, Ki: 0.6 nM
|
5-HT1A Receptor, Ki: 2.9 nM
5-HT1 Receptor, Ki: 18 nM
|
|
|
|
|
|
Pan Modulator
|
99.51% |
Pipamperone |
5-HT2A Receptor, pKi: 8.2
5-HT2C Receptor, pKi: 6.9
|
|
|
|
|
|
|
Pan Antagonist
|
99.89% |
(Rac)-Rotigotine hydrochloride |
5-HT2B Receptor, Ki: 27 nM
|
5-HT1A Receptor, Ki: 30 nM
|
|
|
|
|
|
Pan Agonist
|
97.76% |
Ziprasidone hydrochloride monohydrate |
|
Rat 5-HT1A Receptor, : 3.4 nM
human 5-HT1A Receptor, : 2.5 nM
|
|
|
|
|
|
Pan Antagonist
|
99.83% |
Ocaperidone |
5-HT2 Receptor, Ki: 0.14 nM
|
5-HT1A Receptor, pEC50: 7.6 (h5-HT1A)
5-HT1A Receptor, pKi: 8.08 (h5-HT1A)
|
|
|
|
|
|
Pan Modulator
|
98.55% |
SB 271046 Hydrochloride |
5-HT2A Receptor, pKi: 5.62
5-HT2B Receptor, pKi: 5.41
Human 5-HT2C Receptor, pKi: 5.73
|
5-HT1D Receptor, pKi: 6.55
5-HT1A Receptor, pKi: 6.35
5-HT1B Receptor, pKi: 6.05
5-HT1F Receptor, pKi: 5.95
5-HT1E Receptor, pKi: <4.99
|
|
|
5-HT6 Receptor, pKi: 8.92-9.02
|
5-HT7 Receptor, pKi: 5.39
|
5-HT4 Receptor, pKi: 5.27
|
Pan Antagonist
|
99.06% |
Setiptiline |
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
Pan Modulator
|
96.54% |
SB 243213 dihydrochloride |
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
Pan Antagonist
|
>99.0% |
Piromelatine |
5-HT2B Receptor (Antagonist)
|
5-HT1A Receptor (Agonist)
5-HT1D Receptor (Agonist)
|
|
|
|
|
|
Pan Modulator
|
99.21% |
SB 243213 hydrochloride |
Human 5-HT2C Receptor, pKi: 9.37
Human 5-HT2A Receptor, pKi: 7.01
human 5-HT2B Receptor, pKi: 7.2
|
human 5-HT1A Receptor, pKi: <5.3
human 5-HT1B Receptor, pKi: 5.5
human 5-HT1D Receptor, pKi: 6.32
human 5-HT1E Receptor, pKi: <5.4
human 5-HT1F Receptor, pKi: 5.35
|
|
|
Human 5-HT6 Receptor, pKi: 6.5
|
Human 5-HT7 Receptor , pKi: 5.64
|
|
Pan Antagonist
|
|
Eltoprazine |
|
5-HT1A Receptor
5-HT1B Receptor
|
|
|
|
|
|
Pan Modulator
|
>95.0% |
5-HT6/7 antagonist 1 |
|
|
|
|
|
|
|
Pan Antagonist
|
|
Spiperone hydrochloride |
5-HT2A Receptor, Ki: 1 nM
|
5-HT1A Receptor, Ki: 49 nM
|
|
|
|
|
|
Pan Antagonist
|
|
LY320135 |
5-HT2 Receptor, Ki: 6.4 μM
|
|
|
|
|
|
|
Pan Modulator
|
|
Mirtazapine D3 |
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Isopteropodine |
|
|
|
|
|
|
|
Pan Agonist
|
|
Brexpiprazole S-oxide D8 |
5-HT2A Receptor, Ki: 0.47 nM
|
5-HT1A Receptor, Ki: 0.12 nM
|
|
|
|
|
|
Pan Modulator
|
|
Cyamemazine |
5-HT2A Receptor, Ki: 1.5 nM
5-HT2C Receptor, Ki: 12 nM
|
|
5-HT3 Receptor, Ki: 75 nM
|
|
|
|
|
Pan Antagonist
|
>99.0% |
5-HT1A modulator 1 |
5-HT2A Receptor, IC50: 500 nM
5-HT2C Receptor, IC50: 4000 nM
|
|
|
|
|
|
|
Pan Modulator
|
|
Perospirone hydrochloride |
5-HT2A Receptor, Ki: 0.6 nM
|
5-HT1A Receptor, Ki: 2.9 nM
5-HT1 Receptor, Ki: 18 nM
|
|
|
|
|
|
Pan Modulator
|
|
Eplivanserin |
5-HT2 Receptor, IC50: 5.8 nM (in rat cortical membrane)
5-HT2 Receptor, Ki: 1.14 nM
|
|
|
|
|
|
|
Pan Antagonist
|
|
AR-A 2 |
5-HT2A Receptor, Ki: 339 nM
|
5-HT1A Receptor, Ki: 3070 nM
5-HT1B/D Receptor, Ki: 20 nM
|
|
|
|
|
|
Pan Antagonist
|
|
TIK-301 |
5-HT2C Receptor
5-HT2B Receptor
|
|
|
|
|
|
|
Pan Antagonist
|
|
BGC20-761 |
Human 5-HT2A Receptor, Ki: 69 nM
|
|
|
|
Human 5-HT6 Receptor, Ki: 20 nM
|
|
|
Pan Antagonist
|
|
SB228357 |
5-HT2A Receptor, pKi: 6.9
5-HT2C Receptor, pKi: 9
5-HT2B Receptor, pKi: 8
|
|
|
|
|
|
|
Pan Antagonist
|
>99.0% |
Brilaroxazine |
5-HT2A Receptor, Ki: 2.5 nM
5-HT2B Receptor, Ki: 0.19 nM
|
5-HT1A Receptor, Ki: 1.5 nM
|
|
|
|
5-HT7 Receptor, Ki: 2.7 nM
|
|
Pan Modulator
|
|
GR 113808 |
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
Pan Antagonist
|
|
(S)-Mirtazapine |
|
|
|
|
|
|
|
Pan Antagonist
|
|
SB-200646 |
5-HT2B Receptor, pKi: 7.5
5-HT2C Receptor, pKi: 6.9
5-HT2A Receptor, pKi: 5.2
|
|
|
|
|
|
|
Pan Antagonist
|
|
cis-(Z)-Flupentixol dihydrochloride |
5-HT2A Receptor, Ki: 7 nM
|
|
|
|
|
|
|
Pan Antagonist
|
|
Brexpiprazole S-oxide |
5-HT2A Receptor, Ki: 0.47 nM
|
5-HT1A Receptor, Ki: 0.12 nM
|
|
|
|
|
|
Pan Modulator
|
|
Iloperidone hydrochloride |
Rat 5-HT2 Receptor, Ki: 3.1 nM
Human 5-HT2A Receptor, Ki: 5.6 nM
Human 5-HT2C Receptor, Ki: 42.8 nM
|
Rat 5-HT1A Receptor, Ki: 168 nM
|
|
|
Rat 5-HT6 Receptor, Ki: 42.7 nM
|
Rat 5-HT7 Receptor, Ki: 21.6 nM
|
|
Pan Antagonist
|
|
Ziprasidone hydrochloride |
|
Rat 5-HT1A Receptor, Ki: 3.4 nM
human 5-HT1A Receptor, Ki: 2.5 nM
|
|
|
|
|
|
Pan Antagonist
|
|
Nexopamil racemate |
|
|
|
|
|
|
|
Pan
|
|
Deramciclane |
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
Pan Antagonist
|
|
Irindalone |
|
|
|
|
|
|
|
Pan Antagonist
|
|
Paliperidone |
|
|
|
|
|
|
|
Antagonist
|
99.87% |
Setiptiline maleate |
5-HT2A Receptor
5-HT2C Receptor
|
|
|
|
|
|
|
Antagonist
|
98.18% |
Paliperidone palmitate |
|
|
|
|
|
|
|
Antagonist
|
98.16% |